Pfizer Inc. $PFE Shares Sold by Sapient Capital LLC

Key Points

• Sapient Capital slashed its Pfizer position by 93.6% in the third quarter, selling 399,889 shares and retaining 27,179 shares valued at approximately $775,000. Institutional investors overall own 68.36% of Pfizer’s stock.
• Pfizer recently reported quarterly EPS of $0.77, beating estimates of $0.68, while revenue rose 2.6% year over year to $15.03 billion. The company’s 2026 EPS guidance is $2.80–$3.00.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $28.61. Pfizer also declared a quarterly dividend of $0.43 per share, representing a 6.2% yield, though its elevated payout ratio and balance-sheet concerns remain risks.

Sapient Capital LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 93.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,179 shares of the biopharmaceutical company's stock after selling 399,889 shares during the quarter. Sapient Capital LLC's holdings in Pfizer were worth $775,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atwood & Palmer Inc. lifted its stake in Pfizer by 63.8% in the 3rd quarter. Atwood & Palmer Inc. now owns 16,261 shares of the biopharmaceutical company's stock valued at $464,000 after acquiring an additional 6,332 shares in the last quarter. Apella Capital LLC grew its stake in shares of Pfizer by 22.2% during the 3rd quarter. Apella Capital LLC now owns 56,927 shares of the biopharmaceutical company's stock worth $1,594,000 after acquiring an additional 10,327 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Pfizer by 1.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 172,660 shares of the biopharmaceutical company's stock worth $4,924,000 after acquiring an additional 3,282 shares in the last quarter. Quintet Private Bank Europe S.A. raised its holdings in shares of Pfizer by 40.6% in the third quarter. Quintet Private Bank Europe S.A. now owns 684,746 shares of the biopharmaceutical company's stock valued at $19,529,000 after purchasing an additional 197,811 shares during the last quarter. Finally, Vann Equity Management LLC bought a new stake in shares of Pfizer in the third quarter worth $325,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA expands TUKYSA opportunity: The FDA approved TUKYSA (tucatinib) with trastuzumab and pertuzumab as a frontline maintenance treatment for adults with unresectable or metastatic HER2-positive breast cancer. The expanded label moves the drug into an earlier treatment setting, potentially increasing its addressable market and supporting Pfizer’s oncology growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Promising pipeline developments: Positive Phase 3 results for LITFULO in nonsegmental vitiligo showed meaningful facial and total-body repigmentation with favorable tolerability. Pfizer plans regulatory submissions, which could broaden the drug’s immunology-market opportunity. Pfizer Posted Positive Phase 3 Vitiligo Results
• Positive Sentiment: Potential earnings support: Analysts note Pfizer’s history of earnings surprises and suggest the company currently has favorable conditions for another quarterly beat. Oncology product sales, biosimilars, and late-stage pipeline progress will be important ahead of third-quarter results. Will Pfizer Beat Estimates Again?
• Neutral Sentiment: Analyst target increase: Cantor Fitzgerald raised its price target from $27 to $28 while retaining a “neutral” rating, implying limited near-term upside and signaling that valuation and execution risks remain balanced. Cantor Fitzgerald Pfizer Price Target Update
• Negative Sentiment: Dividend and balance-sheet concerns: Pfizer declared a quarterly dividend of $0.43 per share, but commentary warns that the roughly 6% yield, frozen payout, debt, and a recent multibillion-dollar write-down may raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Restructuring and earnings pressure: Pfizer plans to cut about 330 jobs at its Sicily facility, while analysts describe an increasingly challenging period. The company’s cost reductions and recent loss per share underscore concerns about post-pandemic revenue declines and execution. Pfizer to Cut Around 330 Jobs in Italy

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Guggenheim reduced their target price on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Bank of America lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. HSBC boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. BMO Capital Markets reduced their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. Finally, Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $28.61.

Pfizer Price Performance

NYSE:PFE opened at $27.82 on Friday. The stock has a market capitalization of $158.59 billion, a PE ratio of 36.61, a P/E/G ratio of 1.88 and a beta of 0.32. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $29.21. The firm has a fifty day simple moving average of $27.62 and a 200 day simple moving average of $26.49. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's dividend payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.